GW Pharmaceuticals Plc ADS (GWPH)

[NYOptionsGuy]

Analyst Reiterates 'Buy' Rating on GW Pharma, Sees >10% Upside

SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/01/23/GWPH-Analyst-Reiterates-Buy-Rating-on-GW-Pharma-Sees-10-Percent-Upside

Leerink Swann's Paul Matteis just reiterated his 'buy' rating on shares of GW Pharmaceuticals Plc (NASDAQ:GWPH) alongside a price target of $153.00 per share. GW Pharma currently has an average price target of $175.00 per share, and out of the four analysts we track that cover GWPH, Matteis's price target is the highest.



With a last trade price of $138.18 for shares of GW Pharma, this price target represents over 10% potential upside.



This decision to lower his price target from $154.00 to $153.00 comes "ahead of CBDV Phase II data in partial-onset seizures in Q1," according to The Fly. "While he acknowledges that is difficult to garner conviction in the Phase 2, his analysis of pre-clinical results - compared side-by-side to cannabidiol - instills him with "cautious optimism" on the program, while he believes that the little credit priced into the stock for CBDV sets up an upside skewed risk/reward on the upcoming data readout this quarter."



To sign up for GW Pharma updates, click here. Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.